Trial *
Publication Liu, STH, medRxiv, 2020
Dates: 24mar2020 to 08apr2020
| Methods | |
| Non-randomized study | |
| Location :
Single center / USA Follow-up duration (days): 14 | |
| Inclusion criteria | Adult patients were identified as eligible for COVID-19 convalescent plasma transfusion under the criteria established for the FDA single patient emergency investigational new drug (eIND) process. |
| Exclusion criteria | NR |
| Type of analysis | Propensity score matching |
| Interventions | |
| Treatment
Convalescent plasma (2 units (approx 250ml X2)) Co-Intervention: Standard care Duration : Over 2-3 h |
|
| Control
Standard care Definition of Standard care: In addition to receiving convalescent plasma transfusion, many recipients received a variety of inpatient pharmacotherapies throughout their hospitalizations (Table 2). There were no significant differences between plasma recipients and control patients in exposures to measured pharmacotherapies, except for therapeutic anticoagulation. | |
| Participants | |
| N analyzed 195 participants (n1=39 / n2= 156) | |
| Characteristics of participants N=* Mean age : 54.3 131 males Severity : Mild: n=0 / Moderate: n=32/ Severe: n=143 Critical: n=20 | |
| Primary outcome | |
| In the register NR | |
| In the report Supplemental O2 requirements and Survival | |
| Documents avalaible |
Protocol NR Statistical plan NR Data-sharing stated Yes |
| Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Moderate |
| Notes | * |